Current Pharmacological Management in Juvenile Huntington’s Disease

Background: The clinical presentation of Juvenile Huntington’s Disease (JHD) can be very different from adult-onset HD with little evidence to guide symptomatic management. Aim: To survey the current use of pharmacological treatments for JHD. Methods: Patients were identified through the HD Associat...

Descripción completa

Detalles Bibliográficos
Autores principales: Robertson, Lisa, Santini, Helen, O'Donovan, Kirsty L, Squitieri, Ferdinando, Barker, Roger A, Rakowicz, Maria, Landwehrmeyer, G. Bernhard, Quarrell, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Huntington Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283037/
https://www.ncbi.nlm.nih.gov/pubmed/22474619
http://dx.doi.org/10.1371/currents.RRN1304
Descripción
Sumario:Background: The clinical presentation of Juvenile Huntington’s Disease (JHD) can be very different from adult-onset HD with little evidence to guide symptomatic management. Aim: To survey the current use of pharmacological treatments for JHD. Methods: Patients were identified through the HD Association, Hospital Doctors and the European Huntington’s Disease Network REGISTRY study. Results: The most commonly prescribed agents were anti-psychotics (24/45), anti-depressants (17/45) and anti-parkinsonian medications (15/45). 5 patients were taking more than 8 medications. Conclusions: The most commonly prescribed group of medication was the anti-psychotic. Many patients were on multiple therapies, highlighting the need to rationalise medications.

Ejemplares similares